In most US academic medical centers, a patient's genomic sequencing results, pathology report, and imaging study are ready within days of each other. But they live in separate departmental silos. The oncologist who needs all three to make a definitive diagnosis waits — on average — 18 days for a complete picture.
For Stage I and Stage II cancers, that 18-day window is the difference between curative intent treatment and palliative care. Pegasi closes it by fusing those signals in real time, the moment the last data point arrives.
Pegasi does not replace your EHR or PACS. We read from them. Our platform sits above your existing infrastructure, normalizing and cross-referencing clinical data streams using a continuously updated oncology knowledge graph trained on peer-reviewed literature and 180,000 de-identified patient cases.
The result is a diagnostic confidence score delivered to the ordering clinician within 90 seconds of data completeness — inside the workflow they already use, with the evidence they need to act. Pegasi is backed by Conscious Venture Lab Accelerator through a seed round investment.
600,000 Americans die from cancer each year. Most late-stage diagnoses could have been caught earlier. That is not a data problem — it is a data integration problem.
Pegasi exists to make early detection the norm, not the exception, at every institution that uses our platform.
A future where no cancer goes undetected past Stage I because clinical data arrived too slowly. Where every oncologist at every institution has access to the same diagnostic intelligence as the world's leading cancer centers.
We measure progress in weeks of lead time gained, not in valuations or press releases.
Build diagnostic intelligence software that integrates with existing clinical infrastructure, surfaces actionable signals to oncologists in real time, and continuously improves through clinical outcome feedback.
We are accountable to patients first, clinicians second, and health system administrators third. That order is non-negotiable.
Founded at Texas Medical Center, Houston
First EHR integration live at Houston Methodist
FDA Breakthrough Device Designation for colorectal detection
12 health system partners, 180K patient cases analyzed
Pegasi was founded by people who worked in hospitals before they worked in startups. That clinical DNA shapes everything — from how we prioritize product features to how we define success metrics.
Our team includes oncologists, clinical informaticists, ML engineers, and regulatory specialists. Weekly clinical advisory sessions with practicing oncologists keep the product grounded in real patient care, not theoretical use cases.
We measure ourselves by weeks of diagnostic lead time gained — not by lines of code shipped or features launched. Every quarter, our clinical outcomes team publishes internal performance reports against partner institution benchmarks.
Every product choice starts with “does this help the patient get diagnosed faster?”
We publish peer-reviewed validation studies. No vanity metrics, no inflated claims.
Oncologists, engineers, and regulatory experts work side by side — not in silos.
Model performance, error rates, and audit logs are shared openly with every partner institution.